November 5, 2011
According to Takeda Pharmaceutical’s consolidated settlement of accounts for April-September 2011, domestic sales of the type 2 diabetes treatment Actos (pioglitazone) fell to ¥18.9 billion, down 22.3% compared to the same period last year. The company attributes the decline to...read more